Sensorion Announces a €15 Million Financing, Extending Cash Runway Until the End of 2025
Sensorion Reports Full-Year 2023 Financial Results and Business Update
Sensorion Announces the Availability of its Financial Report for 2023
Sensorion Announces it Has Met Primary Endpoint for SENS-401 Phase 2a Study
Sensorion has cleared a hurdle on the comeback trail for its hearing loss candidate. Therapeutic concentrations of the drug were detected in the inner ears of all sampled patients during a midstage test, suggesting the small molecule reaches its target area and setting the stage for the release of hearing data later this year.
Sensorion Will Host a Webcast to Announce its 2023 Annual Financial Results
Sensorion Announces Participation in Leerink Partners Biopharma Conference
Sensorion Announces a €50.5 Million Financing With Participation From New and Existing US and European Healthcare Specialist Investors
Sensorion Announces the Completion of Patient Inclusion in Phase 2a of SENS-401
Sensorion Announces its Participation in the Association for Research in